New AI Framework Aims to Personalize HER2-Positive Breast Cancer Treatment
A new artificial intelligence approach published in Nature targets more personalized treatment for HER2-positive breast cancer. The framework focuses on spatially interpretable AI, suggesting it analyzes the spatial patterns within tumor tissue to help guide therapeutic decisions.
HER2-positive breast cancer is characterized by overexpression of the HER2 protein, which drives tumor growth. Dual HER2 blockade typically involves using two targeted therapies together, such as trastuzumab and pertuzumab, to more effectively inhibit HER2 signaling.
The neoadjuvant setting—treatment given before surgery—offers an opportunity to assess tumor response early and adjust strategies accordingly. By applying AI to spatial data from tumor samples, researchers aim to identify patterns that predict which patients are most likely to benefit from this dual blockade approach.
Spatially interpretable AI differs from traditional machine learning by providing insights into why the model makes specific predictions, rather than operating as a black box. This transparency could help clinicians understand the biological basis for treatment recommendations.
While full clinical implementation would require validation in larger studies, this research represents an intersection of computational pathology and precision oncology, potentially bringing AI-driven treatment tailoring closer to routine cancer care.